Introduction {#s1}
============

The therapeutic use of glucocorticoids (GCs) in susceptible individuals increases intraocular pressure (IOP) ([@B15]), which is a major risk factor for GC-induced glaucoma (GIG), an ocular diseases featured with progressive degeneration of retinal ganglion cells (RGCs) ([@B33]). In addition, GIG is similar to primary open angle glaucoma (POAG). Increased IOP can cause vascular insufficiency ([@B47]). and will further lead to vascular endothelial metabolic disorders ([@B18]; [@B16]). GC-induced ocular hypertension results from increased aqueous outflow pathway resistance, morphological and biochemical changes in trabecular meshwork (TM) ([@B7]). Therefore, the effects of GCs on TM cells and other ocular tissues drew increasing attention during last decades. Previous researches suggested that GCs promoted the deposition of TM extracellular matrices (such as fibronectin and type IV collagen), cytosolic protein (such as α-smooth muscle actin), and altered cell cytoskeleton to form cross-linked actin networks ([@B6]; [@B11]). However, the exact pathological mechanisms are still unclear at present. A comprehensive knowledge on the pathogenesis of steroid responders will improve our prevention of IOP elevation and enhance our understanding of steroid induction mechanisms in glaucoma.

Autophagy is an important process to promote cell survival under various stressful conditions, during which various stromal and organelles in the cell are degraded by the lysosomal system. TM cells belong to the post-dividing cells and cannot be removed by re-splitting to remove excess harmful substances. TM cells are continuously under mechanical stress and cell deformation stress due to IOP fluctuations and eye movement ([@B23]). Autophagy, as a mechanism of intracellular self-adaptation protection, maintains TM cell homeostasis and normal function. Previous reviews stated that GCs affected autophagy of various cells, such as osteoblasts, fibroblasts, muscle cells, and lymphocytes ([@B12]; [@B58]). Researches also showed that the autophagy homeostasis of TM cells in the glaucoma aqueous humor outflow pathway changed ([@B13]). In primary cultures of porcine and human TM cells, sustained IOP elevation activated autophagy to response pressure and restore balance ([@B43]).

Our previous researches suggested that the dexamethasone acetate (Dex-Ace) treatment activated autophagy in a time-dependent manner and that the autophagy activity peaked at the fourth week with a plateau of increased IOP for 4 weeks. Thereafter, the continued DEX-Ace treatment did not affect IOP value reduction, but the autophagy activity gradually decreased ([@B55]). Decreased autophagy activity might cause the accumulation of diseased organelles, and produce oxidative damage as well ([@B34]), and might be an indication of progressive dysregulation of TM function.

Rapamycin (RAP), a lipophilic macrolide antibiotic, was created as an antifungal agent, and also has multifunctional nonantibiotic properties ([@B44]). Related researches showed that RAP played an important role in neurological diseases, like Parkinson's disease ([@B36]), nerve injury, Alzheimer disease, and so on ([@B4]). Previous studies stated that RAP improved the survival rate of RGCs in a rat chronic ocular hypertension model of glaucoma ([@B48]) and significantly enhanced autophagy in a monkey chronic hypertensive model ([@B11]). However, the role of RAP in GIG is still unclear.

Studies using systemically or topically treated C57BL/6J mice with DEX showed increased IOP and ultrastructural changes looked like those stated in humans after GC therapy ([@B41]; [@B59]; [@B42]; [@B14]). This research, we used a GIG mouse model to explore the relationship between elevated levels of autophagy and hormonal glaucoma. The effects of RAP, as an mTOR inhibitor and autophagy inducer ([@B34]), on the autophagy levels in GIG mice were investigated. Our results indicated that RAP protected the functions of TM cells *via* upregulating autophagy in GIG.

Materials and Methods {#s2}
=====================

Animal Experiment {#s2_1}
-----------------

Female C57BL/6J mice (6--8 weeks old) were purchased from Beijing HFK Bioscience company and housed at the Center for Animal Experiment/Animal Biosafety Level-III laboratory of Wuhan University. Animal experiment complied with the Association for Research in Vision and Ophthalmology Statement of the Use of Animals in Ophthalmic and Vision Research and carried out according to the regulation of Wuhan University Health Science Center Institutional Animal Care and Use Committee. The mice (16--18 g) were housed under a 12-h light/12-h dark cycle with a free access to standard rodent food and water. The condition of temperature was controlled (22--28°C), as well as the humidity (45--75%).

Reagents {#s2_2}
--------

One hundred and six C57BL/6J mice were divided into four groups randomly: control (vehicle suspension +DMSO), Dex-Ace-treated (Dex-Ace+DMSO), RAP-treated (vehicle suspension +RAP), and Dex-Ace+RAP-treated groups (Dex-Ace+RAP). Dex-Ace (10 mg/ml) or vehicle suspension solution (20 μl) was conjunctival fornix (CF) injected into the tenon of the right eye every 4 d. RAP (4 mg/kg) or 0.1% dimethyl sulfoxide (DMSO, 100 μl) was injected intraperitoneally every other day. Vehicle suspension and DEX-Ace formulation were introduced as a preview study ([@B42]). RAP formulation (0.25 mg/ml in 0.1% DMSO) was stored at -20°C (working fluid).

Periocular CF Injection {#s2_3}
-----------------------

Mice were put into an anesthesia chamber filled with 0.8 L/min oxygen and 2.5% isoflurane to induce general anesthesia. After anesthesia, mice got 1--2 drops of 0.5% proparacaine HCL (S.A. Alcon-couvreur N.V., Belgium) in both eyes. The CF injection was performed as previously noted ([@B42]). Briefly, after lower eyelid was retracted, 20 μl DEX-Ace (10 mg/ml) or vehicle suspension were injected by a 29-gauge insulin syringe immediately under the CF of the right eye in the process of 5--10 s. A 1-ml syringe (Sinopharm, China) was used to inject 100 μl RAP (4 mg/kg) or DMSO (0.1%) into the abdominal cavity.

IOP Measurement {#s2_4}
---------------

Mice were put into the Decapicone, a plastic bag especially for the mouse, which could fully expose the head but restrict its movement ([@B52]). The head of conscious mice was exposed in the hole at the top of the cone and IOP was measured as soon as the mice stayed stable. An effective reading of daytime IOP was obtained weekly at 10 am and 2 pm by applying a probe of tonometer (TonoLab, Colonial Medical, USA) to gently flatten an area of the corneal surface. After baseline IOP was obtained, the right eye was then treated with DEX-Ace or vehicle suspension every 4 d. The IOP of each eye was taken from the average of 3 test values.

Weight Measurement {#s2_5}
------------------

The mice were gently placed on the digital electronic scales (BY-dzc, China) and the weight was measured immediately after the mice stayed stable. Recorded effective reading of body weight weekly at 10 am to an accuracy of 0.01 g. The body weight of each mice was taken from the average of three test values.

RGC Staining {#s2_6}
------------

To estimate changes in the RGC numbers after GIG mice were induced, we counted the number of RGCs in the retinas. BRN3a were used to detect the RGCs in the retina, and the method of retina dissection was as previously described ([@B35]; [@B51]; [@B53]; [@B19]). Briefly, after the mice were sacrificed, the enucleated eyes were fixed in 4% paraformaldehyde for 1 h and flushed in PBS. The retinas were then cut into 4 quadrants and flattened with a fine brush. After incubated with 0.5% Triton X-100 for 15 min, the retinas were incubated with BRN3a antibody (1:200, Millipore, USA) at 4°C overnight. After incubating, the retinas were flushed in PBS three times and then incubated with IgG Cy3 antibody (1:200) for 2 h. Non-overlapping images containing most of the retina in four quadrants were obtained by confocal 155 microscope (zoom = 1,600 folds; TCS SP5 CLSM, Leica, Germany), and the average RGC numbers for four quadrants were quantified.

Transmission Electron Microscopy {#s2_7}
--------------------------------

Unperfused mouse eyes were immediately fixed *via* 2.5% gluataraldehyde (Ted Pella, USA) in phosphate buffer at 4°C for 2 h. The fixative was injected into the eye from a tiny incision in the posterior sclera. Tissues were then fixed with OsO4, dehydrated using ascending alcohol series, and embedded in Epson resin. Ultrathin sections on trabecular organization were cut with an ultramicrotome (EM UC7, Leica), examined using an electron microscope (Tecnai G2 20 TWIN, FEI, USA), and then obtained as described previously ([@B55]).

Immunofluorescence, Hematoxylin and Eosin (H&E) Staining {#s2_8}
--------------------------------------------------------

Mouse eyeballs were enucleated and immediately fixed in 4% paraformaldehyde at 4°C overnight as previously described ([@B17]). After rinsed three times with PBS, the eyes were dehydrated and embedded in paraffin (Paraplast, Sigma-Aldrich, USA). Tissue slices (5 μm) were obtained using a rotation microtome (Thermo Fisher, USA), deparaffinized, and then rehydrated with graded ethanol for 5 min twice each. Antigen retrieval was conducted in citrate buffer. Once cooled, tissue sections were blocked with 10% goat serum and 0.2% Triton-X 100 in a dark and humid chamber for 2 h. After rinse briefly with PBS, the sections were immunolabeled with rabbit polyclonal antibody (α-smooth muscle actin, 1:100, Abcam) and incubated at 4°C overnight. After flushing, the samples were incubated with corresponding secondary antibodies (Alexa goat anti-rabbit 568, 1:500, Thermo Fisher) for 2 h. DAPI (Vector, CA) was used to visualize cellular nuclear. The slices were examined by the Keyence all-in-one fluorescence microscope (Itasca, USA) ([@B27]). For H&E staining, the paraffin section of mice TM tissues were sequentially deparaffinized, rehydrated, stained with hematoxylin and eosin (Sigma-Aldrich), dehydrated and sealed. The slices were visualized and photographed with phase contrast microscope (DMI 1, Leica).

Western Blotting {#s2_9}
----------------

Anterior segment tissues were dissected detailedly and then placed in RIPA lysis buffer (Cell Signaling Technology, USA) ([@B60]). Whole section of the TM with small part of ciliary muscle, iris, and cornea, were contained in the tissues. The BCA Protein Assay kit (Beyotime, China) was used to detect the concentration of total protein. Total protein (40 μg) was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (Beyotime) and transferred to polyvinylidene fluoride membranes (Millipore, USA) followed by the manufacturer's protocol. Membranes were blocked by PBS containing 5% BSA (Cell Signaling) at room temperature for 1 h, and then incubated with primary antibodies (p62, 1:1,000, Cell Signaling; Beclin-1, 1:1,000, Abcam; α-actin, 1:1000, Abcam; Myocilin, 1:500, Abcam; GAPDH, 1:1000, Boster, China) at 4°C overnight. The membranes were washed, incubated with corresponding secondary antibodies (1:3,000, Cell Signaling), and detected by ChemiDocTM XRS+ Imaging System (Bio-Rad, USA). The band intensities were analyzed by ImageJ software.

Statistical Analysis {#s2_10}
--------------------

Statistical analyses were performed with using Prism version 7.0 (GraphPad, USA). Statistical analyses among groups were evaluated *via* one-way analysis of variance (ANOVA), and two groups' comparisons were using unpaired t-test. All data were presented as mean ± SEM for multiple independent experiments. *P* \< 0.05 was considered as statistical significance.

Results and Discussion {#s3}
======================

RAP Inhibited the Elevated IOP Caused by Dex-Ace CF Injection {#s3_1}
-------------------------------------------------------------

The CF injection of Dex-Ace was reported to repeatedly caused obvious and persistent IOP elevation, which related to reduced outflow facility ([@B42]). As our previous researches proved, Dex-Ace induced rapid and significant IOP increase, which peaked at week 4 ([@B55]). In this study, we founded that the IOP in the Dex-Ace-treated group increased at 3 weeks and sustained until 4 weeks. However, IOP had little change in the other three groups. Conscious daytime IOP value was 13.54 ± 0.45 mmHg (n = 18) in the control group, 22.33 ± 0.77 mmHg (n = 18) in the Dex-Ace-treated group, 14.23 ± 0.65 mmHg (n = 18) in the RAP-treated group, and 14.23 ± 0.68 mmHg (n = 18) in the DEX-Ace+RAP-treated group at week 4. Since the third week of treatment, the conscious mouse IOP in the DEX-Ace-treated group continued to be higher than the other three groups by about 4--8 mmHg (*P* \< 0.05) ([**Figure 1**](#f1){ref-type="fig"}).

![RAP reduced Dex-Ace-induced IOP elevation. The conscious mouse IOP was induced significantly by Dex-Ace at 3--4 weeks, but RAP treatment decreased this increase. (n = 20; \*, *p* \< 0.05).](fphar-11-01006-g001){#f1}

RAP Did Not Affect the Body Weight in Mice {#s3_2}
------------------------------------------

In order to evaluate the effect of Dex-Ace treatment and RAP treatment on the whole body of mice, we selected mice with no statistically significant difference (P\> 0.05) in initial body weight comparison. After different treatments, we measured the body weight of mice weekly, and chosen body weight at the end of 0 week, 1 week, 2 week, 3 week, and 4 week for statistical analysis. There was no statistically significant difference between the body weight of each group at 1--4 weeks with its initial weight (P\> 0.05). And no significant difference was seen in body weight comparison between the four groups at 1--4 weeks (P\> 0.05) ([**Figure 2**](#f2){ref-type="fig"}).

![At 0--4 weeks, compared with the other three groups, there was no significant change and fluctuation in the body weight of the Dex-Ace+RAP-treated group. (n = 20; *p* \> 0.05).](fphar-11-01006-g002){#f2}

RAP Protected RGCs From Damages by Dex-Ace Treatment {#s3_3}
----------------------------------------------------

Our previous researches suggested that IOP elevation caused by Dex-Ace treatment in mice resulted in RGC loss by BRN3a immunostaining ([@B55]). In this study, no significant difference was seen in the number of RGCs in the 4 groups of mice at 1 week. At 4 weeks, the number of RGCs in the Dex-Ace-treatment group was significantly decreased (*p* = 0.023), but not in the other three groups. Compared with the Dex-Ace-treated group (326.38 ± 42.86), Dex-Ace+RAP-treated eyes maintained normal RGC numbers in 4 weeks after treatment (388.87 ± 37.25, [**Figure 3**](#f3){ref-type="fig"}).

![RAP increased Dex-Ace-induced reduction of RGCs at 4 weeks. **(A)** Representative BRN3a staining at 1 and 4 weeks. **(B)** Quantification of RGC survival in average four quadrants. There was no statistical difference of RGC number between groups at 1 week (*p* \> 0.05). Compared with the other three groups, the RGCs were significantly reduced in the Dex-Ace group at 4 weeks (scale bar: 25 μm; n = 5; \*, *p* \< 0.05).](fphar-11-01006-g003){#f3}

RAP Recovered Dex-Ace-Induced Ultrastructural and Histological Changes of the TM Cells {#s3_4}
--------------------------------------------------------------------------------------

Dex treatment led to many ultrastructural and histological changes in the TM cells, such as rougher cell membrane edge, poor integrity of the cell membrane, increased bundle-like collagen fibers, and inconspicuous trabecular space. Abnormal mitochondria could also be observed in the cytoplasm. Elastic fibers were increased and disordered, and the outer sheath of the elastic fibers was thick and dense ([**Figure 4B**](#f4){ref-type="fig"}). However, synchronous RAP treatment maintained TM cells a normal morphology with no significant difference compared to the control and RAP-treated groups. The cell membrane of TM cells was smooth and intact, the nuclear staining was uniform, and the basement membrane was relatively intact and continuous. The elastic fibers were surrounded by the thin sheaths, and a large number of collagen fibers were arranged neatly ([**Figures 4A--D**](#f4){ref-type="fig"}).

![RAP normalized Dex-Ace-induced ultrastructural changes of trabecular tissues at 4 weeks. In the control and RAP-treated group **(A**, **C)**, the cell membrane was intact, the nuclear staining was uniform, and the normal mitochondria were arranged in a bundle of collagen fibers. In the Dex-Ace-treated group **(B)** the trabecular space was not obvious. The cytoplasm showed abnormal swelling of the mitochondria, increased and disorderly arranged elastic fibers, thicker, and denser outer sheath of the elastic fibers. In the Dex-Ace+RAP-treated group **(D)**, abnormal swelling of the mitochondria were also showed in the cytoplasm, but the disorderly arranged elastic fibers didn't been found. (\*: trabecular mesh gap; N, nucleus; CF, collagen fiber; EF, elastic fibers; boxes indicate swollen mitochondria; n=5; magnification; 1,700×).](fphar-11-01006-g004){#f4}

In Dex-Ace-treated group, mitochondrial arrangement was disordered, the outline was blurred, the membrane was damaged and dissolved, and the crest disappeared ([**Figure 5A**](#f5){ref-type="fig"}). In addition, it also could be observed that the mitochondria were fused and merge into giant mitochondria, which were rod-shaped and swollen ([**Figure 5B**](#f5){ref-type="fig"}). However, synchronous RAP treatment kept the mitochondria in a normal elliptical shape, with a clear outline and crest, and a normal arrangement ([**Figures 5C, D**](#f5){ref-type="fig"}).

![RAP normalized Dex-Ace-induced ultrastructural changes of mitochondria at 4 weeks. In the Dex-Ace-treated group **(A**, **B)**, the mitochondria were swollen and deformed, mitochondrial crests disappeared, and autophagic mitochondria fused into huge autophagosomes. In the Dex-Ace+RAP-treated group **(C**, **D)**, the mitochondria maintained normal shape and arrangement, and the mitochondrial membrane and crests were clearly visible. (arrows indicate mitochondrial; n=5; magnification: 5,000×).](fphar-11-01006-g005){#f5}

RAP Downregulated Dex-Ace-Induced α-Actin Expression {#s3_5}
----------------------------------------------------

Dex-Ace treatment promoted the deposition of extracellular matrix such as fibronectin ([@B46]), collagens ([@B57]), and α-action ([@B8]) in the trabecular tissues. To assess whether Dex-Ace treatment led to these biochemical changes in GIG mice, we experimented α-smooth muscle actin in the anterior segment tissues. Only the Dex-Ace treatment group showed obvious deposition of α-actin in the trabecular tissues. The Dex-Aced+RAP-treated group did not show an increased expression of α-actin compared to the other groups ([**Figure 6**](#f6){ref-type="fig"}).

![RAP decreased Dex-Ace-induced α-actin expression in mouse trabecular tissues. The fluorescence intensity of α-actin in trabecular tissues was increased in the Dex-Ace-treated group at 4 weeks. (Immunofluorescence: SC, Schlemm's canal; magnification: 400×; scale bar: 50 μm; n = 5; \*, *p* \< 0.05; H&E: Magnification: 200×; scale bar: 50 mm; n = 3).](fphar-11-01006-g006){#f6}

RAP Upregulated TM Cell Autophagy and Downregulated Dex-Ace-Induced GIG-Related Protein Expression {#s3_6}
--------------------------------------------------------------------------------------------------

Our previous studies suggested that numerous autophagy-related structures were discovered in the TM cells after Dex-Ace treatment ([@B55]). Related studies demonstrated RAP increased autophagy *via* inhibiting mTOR ([@B24]). To investigate whether RAP improved the autophagy in the GIG trabecular tissues, autophagy-associated proteins Beclin-1, p62 and LC3 were examined in TM cells. It has been reported that Beclin-1 was an important factor in autophagy, and its autophagic work requires adequate levels of Beclin-1 ([@B54]). p62, as a marker of autophagic flux, accumulates when autophagy is inhibited ([@B3]). When autophagosomes were produced, LC3-I transitioned to LC3-II, which indicated that the content of the LC3-II can laterally reflect the number of autophagosomes ([@B37]). Compared with the control group, the other three groups all showed a gradual increase of Beclin-1 and LC3-II/LC3-I ratio along with a decrease of p62 expression. Furthermore, Beclin-1 and LC3-II/LC3-I ratio were significantly increased and p62 was significantly decreased in the Dex-Ace+RAP-treated group compared to the Dex-Ace-treated group ([**Figures 7A--D**](#f7){ref-type="fig"}). These results demonstrated that autophagy was activated in TM cells of GIG mice, suggesting that RAP upregulated TM cell autophagy in GIG mice.

![RAP enhanced Dex-Ace-reduced TM cell autophagy and Dex-Ace-induced GIG-related protein expression at the 4th week. The relative protein expression levels of Beclin-1 and LC3-II/LC3-I ratio were upregulated, and p62 was downregulated in the Dex-Ace-treated group. RAP treatment further increased beclin-1 and LC3-II/LC3-I ratio, and downregulated p62 **(A, B, C, D)**. Myocilin and a-actin were upregulated in the Dex-Ace-treated group and neutralized by RAP treatment **(A, E, F)**. (n = 6; \*, *p* \< 0.05).](fphar-11-01006-g007){#f7}

Dex treatment also induces several biochemical modifications in the TM cells, such as enhanced accumulation of collagens, fibronectin, and α-smooth muscle actin ([@B42]). RAP downregulated α-actin expression, we next assessed the GIG-related proteins myocilin and α-actin in TM cells. Only the Dex-Ace-treated group showed increased expression of myocilin and α-actin. There was no significant difference of myocilin and α-actin expression in the other three groups ([**Figures 7A, E, F**](#f7){ref-type="fig"}), suggesting that RAP inhibited overexpression of myocilin and α-actin after Dex-Ace treatment.

Discussion {#s4}
==========

GIG is a secondary open angle glaucoma owing to the increased outflow resistance of the trabecular mesh water outflow channel. Many studies explored the effects of GCs on TM tissues and cells. Recently, more and more studies suggested that the autophagy homeostasis of TM cells in the glaucoma outflow pathway changed ([@B29]). Our previous researches indicated that autophagy and the damaging histological changes in the TM tissues were increased in the GIG mice model. In this study, we employed this female GIG mice model to assess whether the use of Dex combined with autophagy activator RAP affected GIG progression. In female mice, hormone injection induced less stress response, such as fight and bite, resulting in less mortality rate. Our results indicated that Dex-Ace treatment induced a fast and obvious elevation of IOP, and increased α-actin and autophagy level in the TM tissues. Moreover, the loss of RGCs after DEX-Ace treatment suggested that the GIG mice model might be able to construct optic neuropathy,

Autophagy, a cellular self-digestion mechanism, is a process that catalyzes the degradation of injured organelles an protein owning to metabolism on body ([@B30]; [@B31]; [@B10]), and will further causes cell apoptosis. Induction of autophagy helps cells adapt to environmental changes by increasing the turnover of proteins and organelles, which in turn affects other cells and metabolic stress, and assist in rebalancing cell and organelle functions, suggesting that activation of autophagy may be the TM cellular original response to stress and balance ([@B32]).

In our studies, mTOR inhibitor RAP was used as an autophagy activator to treat GIG mice. RAP was reported to bind FKBP12 and block the active site of mTOR, resulting in suppressed mTORC1 activity ([@B22]; [@B5]). GIG mice had no IOP elevation under RAP treatment, indicating that RAP-induced autophagy under Dex-Ace-treated conditions controlled IOP in mice. The number of RGCs was significantly increased in Dex-Ace+RAP-treated GIG mice, suggesting RAP protected RGCs from Dex-Ace-induced cell apoptosis, which might inhibit the release of neurotoxic mediators by modulating NF-kB signaling and directly inhibiting RGC apoptosis ([@B37]; [@B48]). Besides, Han et al. pointed out that activated autophagy took part in RAP-mediated inhibition of BV2 microglia activation, suggesting that RAP mediated neuroprotection *via* enhancing autophagy in glaucoma ([@B20]). Moreover, previous studies stated that RAP rescued RGCs *via* downregulating retinal protein REDD1 and working on the mTOR/HIF-1 pathway to vascular endothelial growth factor (VEGF) production in the photoreceptors and retinal pigment epithelial cells case ([@B2]).

Electron microscope observation and immunohistochemical analysis indicated that swollen and increased mitochondria accompanied by overexpressed extracellular matrix were observed in the Dex-Ace-treated mice, but not in Dex-Ace+RAP-treated mice. Damaged mitochondrial quality emphasized the impaired mitochondrial dynamics and mitophagy. Cell damage caused dynamic change in mitochondrial fission, leading to fragmental division of mitochondria and ultimately resulting in cell death ([@B45]). Several publications reported that mitochondria affected oxidative stress ([@B40]). It was also reported that these swollen mitochondria induced transient elevation of cytosolic calcium concentration, which in turn activated the calmodulin-dependent pathways ([@B28]). The mechanism of mitochondrial regulation by RAP is complex and multiplex. RAP might inhibit cytoplasmic mTORC1, causing a reduced hypoxia-inducible factor (HIF)-1a and glycolytic flux to elevate mitochondrial oxygen consumption simultaneously ([@B25]). Another research showed that mTORC1 improved mitochondrial biogenesis and metabolism through transcription factors YY-1 and PGC-1a ([@B9]). Moreover, RAP significantly induced autophagy, and suppressed oxidative stress as well as apoptosis, possibly *via* eliminating injured mitochondria ([@B21]).

In our previous study, Dex-Ace treatment induced autophagy to dispose of damaged TM cells. However, increased abnormal mitochondria indicated that autophagy was insufficient to resolve GC-induced damage ([@B55]). In our current study, the subsequent rise of Beclin-1 and LC3-II/LC3-1 ratio, together with the reduction of the autophagic substrate p62/SQSTM-1, highly suggested the outcome of an ascending autophagic flux after RAP treatment in GIG mice. Previous research stated that p62 might be involved in the neurodegenerative processes because the overexpression of p62 promoted apoptosis through increasing production of caspase-8, and the knockdown of p62 reduced human glioma cell death ([@B56]). Further studies reported that RAP-induced autophagy inhibited axonal growth in cortical neurons and that autophagy negatively regulated axonal extension through the RhoA-ROCK pathway, resulting axonal regeneration of RGCs ([@B1]; [@B39]). Myocilin in TM cells is a short-lived protein ([@B38]; [@B49]). The mutation of myocilin induced a toxic gain in cellular function in the endoplasmic reticulum stress of TM cells through misfolding and abnormal amyloidosis of myocilin protein ([@B50]). In conclusion, an abnormal increase in extracellular matrix caused by Dex-Ace treatment resulted in increased IOP, dysfunctional aqueous humor outflow, TM cell death, and ultimately optic nerve damage ([@B26]). Therefore, enhanced autophagy, which degraded the misfolded myocilin and other increased extracellular matrix, might restore TM function and reduce pathological changes in glaucoma.

Conclusions {#s5}
===========

In this study, the relationship between autophagy and GIG was further observed by using autophagy activators. Our results indicated that RAP ameliorated increased IOP, damaged RGCs, and TM ultrastructure changes induced by Dex-Ace. Our results further elucidated the neuroprotective function of RAP, which supported the concept that RAP was potentially therapeutic target for GIG patients.
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